Replimune Group Inc

REPL is in a Stage 2 advance with EMAs aligned and a pullback into rising 9/20 EMAs providing a disciplined entry. The medium-term structure remains bullish with higher highs/lows, and short-term consolidation shows no exhaustion, making pullbacks into the EMA zone an attractive setup for speculative engagement.

• ↑FDA accelerated approval of TUDRIQEV signals strong regulatory endorsement
• ↑$483.8M cash & equivalents funds operations into Q4 2026
• ↓Q4 2025 net loss of $74.1M underscores heavy cash burn